SCHEMBL7224481

SCHEMBL7224481

CCOC(=O)N1CCN(c2ccccc2O)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
MAPT P10636 6/20 0.68
ALDH1A1 P00352 3/20 0.68
LMNA P02545 2/20 0.60
KDM4E B2RXH2 1/20 0.60
TSHR P16473 2/20 0.55
MAPK1 P28482 2/20 0.55
NPC1 O15118 1/20 0.55
HPGD P15428 1/20 0.55
ALOX15 P16050 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
HSD17B10 Q99714 1/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
PKM P14618 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.53
HTT P42858 2/20 0.52
ALOX12 P18054 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3436308 0.86 MAPT (0.78) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL5362589 0.84 SMN1; SMN2 (0.72) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL11093641 0.84 GAA (0.72) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL15651250 0.84 GAA (0.72) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL3252759 0.82 PKM (0.78) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL30613376 0.82 GAA (0.69) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL2382922 0.82 GAA (0.69) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL13769814 0.81 GAA (0.68) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL7526465 0.81 GAA (0.68) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL27610366 0.80 MAPT (0.74) GAASMN1; SMN2MAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6545037-B2 Thromboxane A2 (TXA2) receptor and 5HT2 serotonergic receptor antagonists; 3-(6-(((4-chlorophenyl)sulphonyl)amino)-3-((2-(4-methyl-1 -piperazinyl)phenoxy)methyl)-5,6, 7,8-tetrahydro-1-naphthyl)propanoic acid for example LES LABORATOIRES SERVIER (FR) 2003-04-08 US disclosed
US-6469011-B2 NITROGEN OXIDE YIELDING AND THROMBOXANE A2 (TXA2) AND SEROTONIN (5HT2) RECEPTOR ANTAGONIST; TREATMENT OF ATHEROTHROMBOTIC CARDIOVASCULAR DISORDERS LES LABORATOIRES SERVIER (FR) 2002-10-22 US disclosed
US-20020137742-A1 Benzenesulfonamide compounds LAVIELLE GILBERT (FR) 2002-09-26 US disclosed
US-20010009915-A1 New benzenesulfonamide compounds LES LABORATOIRES SERVIER (FR) 2001-07-26 US disclosed
US-4358449-A 1-(1,3-Dioxolan-2-ylmethyl)-1H-1,2,4-triazoles and compositions JANSSEN PHARMACEUTICA, N.V. (BE) 1982-11-09 US disclosed
US-4335125-A FUNGICIDES, BACTERICIDES JANSSEN PHARMACEUTICA, N.V. (BE) 1982-06-15 US disclosed
US-4223036-A FUNGICIDES, BACTERICIDES JANSSEN PHARMACEUTICA N.V. (BE) 1980-09-16 US disclosed
US-4144346-A FUNGICIDES, BACTERICIDES JANSSEN PHARMACEUTICA N.V. (BE) 1979-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010009915-A1 New benzenesulfonamide compounds CNR1, CNR2, HTR1A GAA 4753/4885SMN1; SMN2 3231/4885MAPT 4844/4885
US-20020137742-A1 Benzenesulfonamide compounds CNR1, CNR2, HTR1A GAA 4777/4885SMN1; SMN2 2897/4885MAPT 4809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.